BioNTech to look into possible dividend next year
- BioNTech would not look into a proposal for any dividend before next year's annual shareholder meeting.
- Vaccine supply deals lined up for this year alone are worth 12.4 billion euros ($15.1 billion) in revenue for BioNTech.